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Introduction: Detection of epidermal growth factor receptor (EGFR) 
mutations is indispensable to determine an appropriate lung cancer 
treatment. Although retreatment often prolongs survival, how to select 
the appropriate population for retreatment has not been clarified.
Methods: We used novel methods to identify EGFR mutations: 
wild inhibiting polymerase chain reaction (PCR) and quenched 
probe system (WIP-QP) for exon 19 deletions and mutation-biased 
PCR and quenched probe system for L858R. After the detection 
limits were determined, we examined DNA isolated from lung can-
cer specimens and circulating plasma DNA samples of 39 adeno-
carcinoma patients whose primary tumors harbored EGFR exon 19 
deletions or L858R.
Results: Detection limit was 0.005 to 0.04 ng in genomic DNA and 
0.1% to 0.3% in mutant plasmids. The results of cancer tissue speci-
mens were identical to those with existing systems (nucleic acid-
locked nucleic acid PCR clamp or cycleave PCR), except for two 
samples that showed both exon 19 deletions and L858R. One of the 
two samples was confirmed to harbor L858R mutation by allele-
specific oligonucleotide PCR; the other one did not. Exon 19 dele-
tions and L858R were detected in 44.7% and 8.7% of patients, using 
plasma DNA, among those who carried the identical abnormalities 
in primary tumors all of cases that evidenced pathological stage IV 
except for one patient, suggesting that EGFR mutations might be 
preferentially detected in plasma DNA obtained from patients in 
advanced stages. Serial monitoring of these mutations with T790M, 
a gate keeper mutation, demonstrated correlation with disease state.
Conclusions: Our novel detection systems for EGFR mutations 
could be useful not only at the beginning of treatment but also for 
monitoring using plasma DNA for deciding appropriate treatment, 
including rechallenge with EGFR-tyrosine kinase inhibitors.
Key Words: Lung cancer; EGFR activating/sensitive mutations; 
EGFR-TKI; Plasma DNA; Monitoring system.
(J Thorac Oncol. 2012;7: 1369–1381)
Small-molecule tyrosine kinase inhibitors (TKI) such as gefitinib and elrotinib, which target the epidermal growth 
factor receptor (EGFR), were the first molecular target drugs 
to enter clinical use for the treatment of lung cancer.1–3 Several 
clinical trials confirmed that the response rate to EGFR-TKI 
is approximately 70% in patients with EGFR activating/sen-
sitive mutations, such as exon 19 deletions or L858R muta-
tion.4–7 Patients with these mutations evidence significantly 
longer survival than those with wild-type EGFR when treated 
with EGFR-TKI; prognosis (overall survival) has improved to 
27 to 30.5 months. Therefore, examination for the presence or 
absence of EGFR activating/sensitive mutations is indispens-
able to determine an appropriate lung cancer treatment strategy.
As for methods to detect EGFR mutations, direct 
sequencing (DS) was first applied, and is still widely employed, 
to cover new mutations. However, the sensitivity of DS is 
suboptimal for clinical tumor samples because mutant DNA 
needs to constitute over 25% of the total DNA to be detected. 
Therefore, mutation detected by DS could frequently lead to 
false-negative results.8 In recent years, many methods have 
been proposed for improved detection of EGFR mutations in 
lung cancer specimens, and some of them have been universally 
accepted in clinical practice, for example, the nucleic acid–
locked nucleic acid polymerase chain reaction (PCR) clamp 
(PCR clamp) or cycleave PCR techniques. Although these 
methods are more sensitive than DS, with the ability to detect 
mutations in samples containing 1% to 5% mutant alleles,9,10 
they involve complicated procedures and require specialized 
experience. Considering that two thirds of lung cancer patients 
are diagnosed at an inoperable stage, clinical samples such as 
specimens of transbronchial lung biopsy, bronchial washing, 
or pleural effusion, which contain many normal cells, are 
frequently used to detect EGFR mutations. When it is difficult 
to obtain tumor specimens, peripheral blood could be the 
only practical sample for detection of mutations. Therefore, 
a method capable of detecting EGFR mutations in a large 
background of wild-type EGFR genes is desired.
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We developed a novel method to identify EGFR-
activating mutations, wild inhibiting PCR and quenching 
probe system (WIP-QP) for exon 19 deletion and mutation-
biased PCR and quenching probe system (MBP-QP) for exon 
21 L858R mutation. The detection system includes fully auto-
mated genotyping, based on analysis of the probe DNA melting 
curve, which binds the target mutated site using a fluorescent 
guanine quenched probe (QP) system. Originally, we devel-
oped this QP-system for detecting single nucleotide polymor-
phisms, such as CYP2C19, in genotyping, and a JAK2 tyrosine 
kinase mutation, a substitution of valine to phenylalanine at 
codon 617 for diagnosis of chronic myeloproliferative disease 
using a cell-free system.11,12 Based on these technologies, we 
recently developed the MBP-QP method, which is a modified 
QP-system aimed at higher sensitivity to detect EGFR T790M 
mutation, a gate keeper mutation related to acquired resistance 
to EGFR-TKI.13–16 Using the MBP-QP method, we succeeded 
at detecting T790M using plasma DNA with a detection rate 
of 53% among lung cancer patients who acquired resistance 
to EGFR-TKI.17 We then undertook to develop new detec-
tion systems for EGFR activating/sensitive mutations such as 
L858R and exon 19 deletions using plasma DNA. Although the 
MBP-QP method could be applied to the detection of L858R, 
as with T790M, it was necessary to develop a new system, 
WIP-QP, for detection of exon 19 deletions. WIP-QP enabled 
us to automatically detect 14 of 17 types of exon 19 deletions 
reported in lung cancer specimens, which consisted of 97% of 
exon 19 deletions among lung cancer patients.18–20
In addition to its usefulness at the beginning of treat-
ment, monitoring of EGFR mutations with plasma DNA 
would be beneficial for predicting efficacy of EGFR-TKI. 
Although 70% of lung cancer patients with EGFR activating/
sensitive mutations benefit from EGFR-TKI, they eventu-
ally acquire resistance to EGFR-TKI.13–16 Retreatment with 
EGFR-TKI, especially gefitinib, often produces long survival 
for advanced lung cancer patients, sometimes over 5 years 
after diagnosis.21,22 However, it has yet to be elucidated what 
subpopulation of patients is amenable to rechallenge with 
EGFR-TKI. Because about 50% of lung cancer patients with 
acquired resistance to EGFR-TKI carry a T790M mutation, 
monitoring of EGFR activating/sensitive mutations in com-
bination with T790M using plasma DNA should prove useful 
for predicting effectiveness of rechallenge with EGFR-TKI. 
The purpose of developing new detection systems for EGFR 
activating/sensitive mutations is not only the pursuit of a more 
sensitive method at the beginning of treatment but also inves-
tigating the possibility of monitoring the presence of EGFR 
mutations in plasma DNA for deciding appropriate treatment 
including rechallenge with EGFR-TKI.
PATIENTS AND METHODS
Cell Lines and Patient Selection
Human lung cancer cell lines H1975, HCC4006, 
and A549 were purchased from the American Type Culture 
Collection (Manassas, VA). PC-9 was kindly provided by 
Masami Suganuma of the Saitama National Cancer Center 
Hospital. HCC4006, PC-9, and A549 cells were cultured in 
Roswell Park Memorial Institute medium-1640 supplemented 
with 10% fetal bovine serum at 37°C in 5% carbon dioxide. 
H1975 cells were cultured in Roswell Park Memorial Institute 
medium-1640 containing 10 mM HEPES, 1 mM sodium 
pyruvate, 2.5 g/liter glucose, and 1.5 g/liter sodium bicarbon-
ate, supplemented with 10% fetal bovine serum. Lung can-
cer tissue and blood specimens were obtained from 39 lung 
adenocarcinoma patients evidencing EGFR exon 19 deletion 
or L858R mutation. Cancer patients underwent treatment 
with operation or chemotherapy at Saga University Hospital 
or Saga Prefectural Hospital Koseikan from 2000 to 2010. 
Clinical stage was determined according to the criteria of 
the 6th edition of the International Union Against Cancer at 
the time plasma samples were collected.23 The study protocol 
was approved by the Clinical Research Ethics Committees of 
Saga University and Saga Prefectural Hospital Koseikan. All 
patients gave informed consent for blood and tissue specimen 
collection, and genomic testing was done according to the 
Declaration of Helsinki.
The WIP-QP Method and 
Preparation of Control Plasmid
To detect EGFR exon 19 deletions, we developed 
the WIP-QP method using i-densy (ARKRAY Inc., Kyoto, 
Japan) (Figure 1A). WIP-QP is a fully automated system with 
two steps: WIP and QP. Wild inhibitor nucleic acid (WI) is 
complementary to wild-type sequence corresponding to the 
deletion part. WI suppresses amplification of the wild-type 
sequence by binding to wild-type template but not mutant, 
resulting in preferential amplification of the mutant sequence. 
PCR conditions were 95°C for 60 seconds, 20 cycles at 95°C 
for 1 second and 54°C for 12 seconds, and 50 cycles at 95°C 
for 1 seconds and 54°C for 15 seconds. Primer sets used were 
as follows: 5′-TCTCTCTGTCATAGGGACTC-3′ for the for-
ward primer and 5′-GAAACTCACATCGAGGATTTC-3′ 
for the reverse primer. The WI sequence was 
5′-CCCGTCGCTATCAAGGAATTAAGAGAAGCAACAT 
CTCCGA-3′. Presence of deletion in amplified sequences 
was determined by monitoring the fluorescence intensity 
of a TAMRA-conjugated, guanine-specific quench fluo-
rophore probe (QProbe; J-Bio21, Tokyo, Japan), which is 
complementary to wild-type sequence containing deletion 
part 5′-(TAMRA)-CCCGTCGCTATCAAGTAATTAAGA
GAAGCAACA-3′. When the QProbe was hybridized with 
the target DNA, its fluorescence was quenched by the gua-
nine in the target sequence, which is complementary to the 
modified cytosine at the 5′ end. After PCR was completed, 
the temperature was reduced to 40°C and then gradually 
increased. Fluorescence intensity was measured at different 
temperatures to identify wild-type and mutant amplicons, as 
fluorescence intensity depends on QProbe dissociation from 
the amplicon: wild-type dissociates at 64.5°C and mutant 
at 50.5°C to 53.5°C. The control plasmid was prepared by 
GenScript USA Inc. as follows: a 287-bp DNA fragment 
(Accession No. NT_033968.6 4831717–4832003) was 
obtained by PCR, purified, and subcloned into the pUC57 
vector. The criterion for declaring a sample positive for muta-
tion with the WIP-QP method was that the ratio of areas 
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FIGURE 1. A, Principles of the 
WIP-QP method for detecting 
exon 19 deletions. It involves the 
following two steps: wild inhibit-
ing PCR (WIP) and a quenching 
probe (QP) system. Wild Inhibitor 
nucleic acid (WI), complementary 
to wild type sequence correspond-
ing to the deletion part, suppresses 
amplification of the wild type 
sequence by binding to wild-type 
template but not mutant, result-
ing in preferential amplification of 
the mutant sequence. Deletions 
in the amplified sequences were 
determined by the QP system, in 
which the fluorescence intensity 
of a TAMRA-conjugated guanine-
specific quench fluorophore probe 
(QProbe) complementary to the 
wild type sequence containing 
the deletion part is monitored. 
Fluorescence intensity at differ-
ent dissociation temperatures was 
measured to identify wild-type 
and mutant amplicons. B, Results 
with the WIP-QP method using 
control plasmids and genomic 
DNA isolated from cancer cell 
lines are shown. Mutant plas-
mids and wild type were mixed 
in the indicated ratios, and the 
assays were performed. As for the 
genomic DNA, DNA isolated from 
PC-9 or HCC4006 cells were mixed 
with A549, and the assays were 
performed. PC-9 and HCC4006 
respectively contain the exon 19 
deletion alleles Del E746-A750 and 
Del L747-A750. Both alleles were 
wild type of exon 19 in A549. Black 
and red arrows indicate wild type 
and mutant, respectively.
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under mutation and wild-type peaks, multiplied by 100, was 
40 or greater (Supplementary Figure, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A329). This criterion 
was chosen after examination of six different variations of 
annealing temperature and mixture volume.
The MBP-QP Method and 
Preparation of Control Plasmid
To detect the EGFR L858R mutation, we developed the 
MBP-QP method using i-densy (Figure 2A). The MBP-QP 
method was already established for detecting EGFR T790M 
mutation, which is observed after acquired resistance to EGFR-
TKI as described previously.17 At the MBP step, PCR conditions 
were 95°C for 60 seconds and 50 cycles at 95°C for 1 second 
and 60°C for 15 seconds. The primer sets used were as fol-
lows: 5′-AGGAACGTACTGGTGAAAACACCGC-3′ for the 
forward primer and 5′-ACACTACCCAGCAGTTTAGCCC-3′ 
for the reverse primer of the mutant sequence, and 
5′-GACTACCCAGCAGTATGGCCA-3′ for the reverse primer 
of the wild-type sequence. The reverse primers contained five 
bases of random sequence at the 5′-end (underscored). Bold 
characters indicate the mutated base. The presence of L858R 
in the amplified sequences was determined by monitoring 
the fluorescence intensity of a TAMRA-conjugated, guanine-
specific quench fluorophore probe , which is complementary 
to L858R: 5′-TTGGCCCGCCCAAAATC-(TAMRA)-3′. The 
dissociation temperatures were 60°C for mutant and 52°C for 
wild type. The control plasmids were prepared by GenScript 
USA Inc. as follows: a 300-bp DNA fragment (Accession 
No. NT_033968.6 4848736–4849035) was obtained by PCR, 
purified, and subcloned into the pUC57 vector. The criterion 
for declaring a sample positive for mutation with the MBP-QP 
method was an area under the mutation peak of 4.4 or more 
(Supplementary Figure, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A329). This is half of the area under 
the peak obtained by the mixture containing 0.3% mutant. 
Examinations using allele-specific oligonucleotide PCR were 
performed, as described elsewhere,24 to confirm the mutations 
in two samples where the results of MBP-QP and DS were not 
consistent.
Tumor DNA Extraction and Detection of 
EGFR Exon 19 Deletions and L858R
Genomic DNA was isolated from specimens using 
QIAamp DNA mini kits (QIAGEN, Hilden, Germany) accord-
ing to the manufacturer’s instructions. Mutations in exons 19 
and 21 were determined by DS, peptide nucleic acid-locked 
nucleic acid PCR clamp, or cycleave PCR techniques, in 
addition to WIP-QP for exon 19 deletions and MBP-QP for 
L858R. Primers for DS of EGFR have been described pre-
viously.25 The peptide nucleic acid-locked nucleic acid PCR 
clamp assays were conducted by the Mitsubishi Chemical 
Medience Corporation (Tokyo, Japan), and cycleave PCR 
techniques were performed by SRL Inc. (Tokyo, Japan).
Plasma DNA Extraction and Detection 
of EGFR Exon 19 Deletions and L858R
Peripheral blood samples from lung cancer patients 
were collected into tubes containing 3.8% citric acid. Plasma 
was immediately separated from blood cells by 3000 rpm cen-
trifugation at 4oC for 20 minutes. Supernatants were collected 
and stored at −80oC until assays were performed. DNA was 
isolated from 200 μl of patient plasma using a QIAamp DNA 
mini kit according to the manufacturer’s instructions. DNA 
concentration was calculated based on absorbance at 260 nm. 
EGFR exon 19 deletions and L858R were examined using 
WIP-QP and MBP-QP, respectively.
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Statistical Analysis
The χ2 test was used to assess association between 
detection of EGFR mutations in plasma DNA and number of 
organs with cancer involvement, where the latter was dichot-
omized into less than 3 or greater than equal to 3. p values 
are two-tailed; those below 0.01 were considered statistically 
significant. Analyses were conducted using SPSS version 12 
(IBM SPSS Statistics, IBM, Tokyo, Japan).
RESULTS
Detection Limits for Exon 19 
Deletions and L858R Mutation
Using the WIP-QP and MBP-QP methods, we identi-
fied exon 19 deletions and L858R, respectively, in genomic 
DNA isolated from PC-9 and HCC4006 (adenocarcinomas) 
carrying exon 19 deletions and in H1975 (adenocarcinoma) 
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FIGURE 2. A, Principles of the 
MBP-QP method for detecting 
L858R. The MBP-QP method 
consists of two steps: mutation-
biased PCR (MBP) and a quench-
ing probe (QP) system. In MBP, 
primer lengths differ for wild-type 
and mutant sequences, and five 
bases of random sequence are 
added to the reverse primers. 
QProbe is complementary to 
L858R, and the subsequent reac-
tion procedure is the same as with 
the WIP-QP method. B, Results 
with the MBP-QP method using 
control plasmid and genomic 
DNA isolated from H1975 cells 
are shown. Mutant plasmids and 
wild type were mixed in the indi-
cated ratios, and the assays were 
performed. DNA isolated from 
H1975 and A549 were mixed, 
and the assays were performed. 
H1975 cells harbor both a L858R 
and a wild type allele, whereas 
A549 contains only wild-type 
alleles. Black and red arrows 
indicate wild type and mutant, 
respectively.
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carrying the L858R mutation (Figure 1B, 2B). A549 was used 
for wild type for exons 19 and 21. Direct sequencing con-
firmed that PC-9 cells and HCC4006 cells contained an exon 
19 deletion allele (Del E746-A750 and Del L747-A750) and 
that H1975 cells harbored both an L858R and a wild-type 
allele (Figure 1B, 2B). Wild-type and mutant sequences were 
clearly distinguished because their melting temperatures 
(T
m
) differ, as noted in the Patients and Methods section.
Detection limits for exon 19 deletions and L858R 
were assessed using control plasmids containing EGFR 
exon 19 deletions or exon 21 with the L858R mutation, or 
genomic DNA isolated from PC-9, HCC4006, and H1975. 
Fourteen types of exon 19 deletion constructs that are 
observed in 97% of lung cancer exon 19 deletions were 
prepared (Table 1), and the WIP-QP method detected all of 
them (data not shown). Next, we determined detection limits 
for exon 19 deletions and L858R using serial dilutions of 
control plasmids or genomic DNA (Table 2, Figures 1B, 2B). 
Genomic DNA isolated from cell lines was adjusted to 10 ng/μl 
after measurement of the concentration using NanoDrop 
2000C (Thermo Fisher Scientific Inc, Wilmington, DE). 
Serial dilutions of genomic DNA ranged from 0.01 to 
0.0025 ng/4 μl. Control plasmids adjusted to 2 × 104 copies/
ml were diluted from 10 to 1 copy. Detection limits using 
three different types of control plasmids, del E746-A750, 
L747-A750, and L747-P753, revealed a detection limit of 
one copy, which was identical among the three plasmids. The 
detection limit for L858R using a control plasmid was five 
copies. Detection limits using genomic DNA were 0.005 ng 
and 0.04 ng for exon 19 deletions and L858R, respectively. 
When mutant plasmids and wild type were mixed in different 
ratios, the detection limit for exon 19 deletion was 0.1% 
to 0.3% mutant plasmids. Similarly, when genomic DNA 
isolated from mixtures of PC-9 or HCC4006 cells and A549 
cells (wild type) were tested, the detection limit was 0.1% for 
both PC-9 cells and HCC4006 cells. L858R was determined up 
to 0.3% of mutant plasmid, and 0.2% of H1975 cells in the 
mixture with A549 cells.
EGFR Activating/Sensitive Mutation Detection 
and Comparison With Other Methods
Characteristics of 39 adenocarcinoma patients in whom 
the WIP-QP and MBP-QP methods were used to examine DNA 
isolated from lung cancer specimens are shown in Table 3. 
Using other detection systems such as PCR clamp, cycleave 
PCR techniques, or DS, exon 19 deletions and L858R were 
observed in 25 and 14 adenocarcinoma specimens, respec-
tively; all of these were detected by WIP-QP and MBP-QP 
(Table 4). Representative results are shown in Figure 3. The 
mutant peaks varied among patients, suggesting that the num-
ber of mutant alleles contained in cancer specimens may differ. 
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TABLE 1.  Types of Exon 19 Deletions Detectable by wild 
inhibiting polymerase chain reaction and quenching probe 
system
E746_A750del (2235–2249)
E746_A750del (2236–2250)
L747_E749del,A750P
L747-T751del
L747_S752del,P753S
L747-A750del P ins
L747-S752 del S ins
E746-T751 del V ins
L747-A750del
L747-S752 del Q ins
E747-S752 del V ins
L747_S752del,E746V
E746-A750 del V ins
L747-E749,T751-S752 del
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L858R mutation was newly detected with the MBP-QP method 
in two samples previously examined by direct sequencing. One 
sample was a surgical tumor specimen, and the other was a 
specimen of transbronchial lung biopsy. To judge credibility of 
this result, those two samples were also examined using allele-
specific oligonucleotide PCR; the detection limit for L858R 
mutation using control plasmid was 2 copies (data not shown). 
As a result, one of the two samples was confirmed to harbor 
L858R mutation. We also examined an additional 45 DNA sam-
ples in a blinded fashion to confirm the validity of these assays, 
and same results were obtained in all samples (Supplementary 
Table 1, Supplemental Digital Content 2, http://links.lww.com/
JTO/A330).
EGFR Activating/Sensitive Mutations 
Preferentially Detected in Plasma DNA of 
Advanced Stage Lung Cancer Patients
Using the WIP-QP and MBP-QP methods, we examined 
70 plasma DNA samples of 39 lung adenocarcinoma patients 
who harbored EGFR exon 19 deletions or L858R mutation in 
their primary tumor. Plasma DNA samples were collected from 
the same patient one to five times, especially before treatment, 
during successful treatment, and during the period of progres-
sive disease, if possible. Exon 19 deletion was detected in 44.7% 
of the patients (21 of 47) whose primary tumors carried exon 
19 deletions (Table 5). Similarly, L858R mutation was detected 
in 8.7% of the patients (2of 23). These plasma DNA samples 
were obtained from patients in pathological stage IV, with the 
exception of one patient, suggesting that EGFR mutations can 
be preferentially detected with plasma DNA obtained from 
patients in advanced stage. When study patients were divided 
into two groups according to number of organs with cancer 
involvement (<3 or ≥3), EGFR mutations were more frequently 
detected in plasma DNA of patients with involvement of 3 
or more organs, but the result for L858R was not statistically 
significant (Table 6). Serial analysis of EGFR mutations using 
plasma DNA produced results with representative cases shown 
in Figure 4. Case 1 recurred as intrapulmonary metastasis after 
surgery. When recurrence was restricted to the lungs, L858R 
was not detected in plasma DNA but appeared after metastatic 
lesions spread to the liver (Figure 4A). On the contrary, L858R 
was detected before chemotherapy and disappeared after tumor 
regression in case 2 (Figure 4B). These data suggest that detec-
tion of EGFR mutations might be correlated with the total vol-
ume of tumor in the body.
Combination of EGFR Activating/Sensitive 
Mutations With T790M in Plasma DNA 
During Treatment for Lung Adenocarinoma
Monitoring of both EGFR activating/sensitive muta-
tion and T790M with plasma DNA was performed in two 
lung adenocarcinoma patients using our recently established 
noninvasive monitoring system for EGFR T790M mutation. 
TABLE 2.  Detection of EGFR Mutations Using MBP-QP 
Method (L858R) and WIP-QP Method (Exon 19 Deletions)
Threshold
Quantity Ratio (%)
Exon 19 deletions
Plasmid
Del E746-A750 1 copy 0.1*
Del L747-A750 1 copy 0.1*
Del L747-P753 1 copy 0.3*
Genomic DNA
PC-9 (Del E746-A750) 0.005 ng 0.1†
HCC4006 (Del L747-A750) 0.005 ng 0.1†
L858R
Plasmid 5 copies 0.3*
Genomic DNA 0.04 ng 0.2†
*Percentage of control plasmids carrying the exon 19 deletions or L858R relative to 
the amount of wild-type plasmid in the mixture.
†Percentage of genomic DNA isolated from PC9 (exon 19 deletion), HCC4006 
(exon 19 deletion). or H1975 (L858R) in the mixture with that from A549 (wild).
EGFR, epidermal growth factor; MBP, mutation-biased polymerase chain reaction; 
QP, quenched probe system; WIP, wild inhibiting polymerase chain reaction.
TABLE 3. Characteristics of Lung Adenocarcinoma Patients
Total n = 39
Age 63.7 ± 12.6
Sex
Men 19 (48.7%)
Women 20 (51.3%)
Smoking status
Smoker 18 (46.2%)
Never smoker 21 (53.8%)
Stage
I 16 (41.0%)
II 1 (2.6%)
III 7 (17.9%)
IV 15 (38.5%)
EGFR mutation
L858R 14 (35.9%)
Exon 19 deletion 25 (64.1%)
EGFR, epidermal growth factor receptor.
TABLE 4.  Detection of Exon 19 Deletions and L858R in 
Primary Lesions
PCR clamp, Cycleave or 
DS*
WIP-QP (exon 19) and MBP-QP (L858R)†
Mutant Wild type
Exon 19
Mutant (n = 25) 25 0
Wild type (n = 12) 0 12
L858R
Mutant (n = 14) 14 0
Wild type (n = 24) 2 22
*PCR clamp and cycleve were used for detection of mutations of some surgical specimens, 
and all transbronchial biopsies, and DS was used for that of some surgical specimens.
†Detection of Exon 19 deletions and L858R using WIP-QP and MBP-QP were 
performed using genomic DNA, which could be available to these systems.
PCR clamp, peptide nucleic acid-locked nucleic acid PCR lamp assay; Cycleave, 
cycleave PCR technique; DS, direct sequencing; WIP, wild inhibiting polymerase chain 
reaction; QPethod; MBP-QP, mutation biased PCR-quenching probe system.
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EGFR T790M is a gate keeper mutation related to acquired 
resistance to EGFR-TKI based on the MBP-QP method.17 
One of the patients recurred after surgery and gefitinib was 
prescribed because of the detection of exon 19 deletion in her 
primary tumor (Figure 5A). Before treatment with gefitinib, 
neither exon 19 deletion nor T790M was observed in plasma 
DNA. After discontinuance of gefitinib because of severe 
dermatitis, she underwent chemotherapy. When intrapulmo-
nary metastasis developed despite chemotherapy, exon 19 
deletion was detected but not T790M. EGFR-TKI, erlotinib, 
elicited tumor response and was continued for 1 year. When 
the patient acquired resistance to EGFR-TKI, both exon 19 
deletion and T790M were detected in plasma DNA. The other 
patient was in stage IV, received chemotherapy, and gefitinib 
was prescribed as the second-line therapy (Figure 5B). Six 
months after discontinuing gefitinib because of lung injury, 
cancer recurred as a distant metastasis in the spinal cord 
and erlotinib was started. Gait disturbance as a manifesta-
tion of spinal cord metastasis improved, but he subsequently 
acquired resistance to erlotinib with multiple metastases in 
bone and intrapulmonary regions. At that time, both exon 
19 deletion and T790M were observed in plasma DNA, but 
T790M disappeared after chemotherapy.
DISCUSSION
We have established novel, fully automated systems, 
WIP-QP for exon 19 deletions, and MBP-QP for L858R, that 
TABLE 5.  Detection of Exon 19 Deletions and L858R With 
Plasma DNA Using MBP-QP
Primary Lesions*
Plasma DNA†
Mutant Wild type
Exon 19 (25 patients) 13 (52.0%) 12
 Mutant (47 samples‡) 21 (44.7%) 26
 Wild type (23 samples) 0 23
L858R (14 patients) 2 (14.3%) 12
 Mutant (23 samples) 2 (8.7%) 21
 Wild type (47 samples) 0 47
*Exon 19 deletions and L858R in primary tumors were determined by direct sequencing, 
peptide nucleic acid-locked nucleic acid PCR clamp, or cycleave PCR technique.
†Exon 19 deletions and L858R in plasma DNA were determined by wild inhibiting 
PCR-quenching probe method and MBP-QP, respectively.
‡Plasma DNA samples were collected from the same patient one to five times, 
especially before and after treatment.
MBP-QP, mutation biased polymerase chian reaction-quenching probe system
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FIGURE 3.  Results with the MBP-QP and WIP-QP methods for detecting L858R and exon 19 deletion, respectively, using lung 
cancer tissues. Black and red arrows indicate wild type and mutant, respectively.
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are reliable and useful for detecting EGFR mutations. Our 
systems compare favorably with existing systems, produc-
ing results with tumor specimens from lung cancer patients 
that were identical to those obtained using PCR clamp assay, 
cycleave PCR, and DS. As for sensitivity, the methods can 
detect as few as 0.1% to 0.3% mutant alleles.
Most notably, because of their high sensitivity, our 
systems could detect the mutations in plasma DNA. Two 
noteworthy findings were that exon 19 deletions were more 
frequently detected in plasma DNA than L858R, and these 
mutations were detected more often in a patient with wide-
spread metastasis. One reason for the difference in detec-
tion rates between exon 19 deletions and L858R may be a 
difference in the sensitivities of the two systems, the detec-
tion threshold of exon 19 deletions being slightly lower than 
that for L858R (Table 2). Another possibility is that DNA 
involved with exon 19 deletions could be released more eas-
ily than that with L858R. Plasma DNA has been reported to 
originate from cell lysis, apoptosis, and active-released DNA 
from cancer cells and circulating tumor cells.26,27 Although the 
biological differences between exon 19 deletions and L858R 
mutation has not been clarified, a transgenic animal model 
carrying exon 19 deletions led to papillary adenocarcinoma, 
whereas bronchioloalveolar carcinoma occurred in those car-
rying the L858R mutation.28 We previously reported clinico-
pathological differences between exon 19 deletions and the 
L858R mutation:25 93% of cases (13 of 14) with L858R were 
adenocarcinomas with features of bronchioloalveolar carci-
noma compared with 53% of cases (8 of 15) with exon 19 
deletions. This suggests that biological characteristics differ 
between exon 19 deletions and L858R. For example, cancer 
cells with exon 19 deletions could be more prone to lysis or 
apoptotic change or are more likely to release cellular DNA 
into peripheral blood.
The association between detection rate of EGFR muta-
tions in plasma DNA and extent of cancer involvement bears 
TABLE 6. EGFR Mutations Were Preferentially Detected in Plasma DNA of Patients With  
Wide-Spread Metastasis
EGFR Mutations of Primary Lesions
Detection With Plasma DNA/Total Cases With EGFR Mutations
Number of Organs With Cancer Involvement
p*≥3 organs <3 organs
Exon 19
Patients (n = 25) 12/18 (66.7%) 1/7 (14.3%) 0.02
Samples+ (n = 47) 20/35 (57.1%) 1/12 (8.3%) <0.01
L858R
Patients (n = 14) 2/4 (50.0%) 0/10 (0%) 0.02
Samples (n = 23) 2/8 (25.0%) 0/15 (0%) 0.04
Total
Patients (n = 39) 14/22 (63.6%) 1/17 (5.6%) <0.01
Samples (n = 70) 22/43 (51.2%) 1/27 (3.7%) <0.01
*The exact p value (two-sided) based on the Pearson χ2 test.
+Plasma DNA samples were collected from the same patient one to five times, especially before and after treatment.
EFGR, epidermal growth factor receptor.
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FIGURE 4. Representative results 
from serial analysis using the MBP-QP 
method to detect the L858R EGFR 
mutation in plasma DNA from lung 
adenocarcinoma patients. A, Case 1 
recurred as intrapulmonary metas-
tasis after surgery, and L858R was 
detected in plasma DNA after appear-
ance of metastatic lesions spread 
to the liver. B, L858R was detected 
before chemotherapy and disap-
peared after tumor regression in case 
2. Black and red arrows indicate wild 
type and mutant, respectively. TKI, 
EGFR-TKI; chemo, chemotherapy; G, 
gefitinib; E, erlotinib; CT, computed 
tomography.
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FIGURE 5. A, Combination of EGFR activating/sensitive mutations with T790M in plasma DNA during treatment for lung 
adenocarcinoma. A serial analysis of the WIP-QP for exon 19 deletion and MBP-QP for T790M in plasma DNA form a lung 
adenocarcinoma patient is shown. Black and red arrows indicate wild type and mutant, respectively. TKI, EGFR-TKI; chemo, 
chemotherapy; G, gefitinib; E, erlotinib; CT, computed tomography. B, Disappearance of T790M from plasma DNA after che-
motherapy. Serial analysis of WIP-QP for exon 19 deletion and MBP-QP for T790M in plasma DNA form a lung adenocarcinoma 
patient is shown. Black and red arrows indicate wild type and mutant, respectively. TKI, EGFR-TKI; chemo, chemotherapy; G, 
gefitinib; E, erlotinib; CT, computed tomography.
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on whether genomic alternations in plasma DNA are correlated 
with prognosis, which remains controversial. In colorectal can-
cers, either KRAS mutation or p16 promoter methylation has 
been observed in 70% of cases using plasma DNA, identical 
to results in cancer tissues, and the detection was correlated 
with prognosis.29 Lee et al.30 reported that number of metastatic 
sites was correlated with level in plasma DNA with lung ade-
nocarcinoma. However, levels in plasma DNA and microsatel-
lite alterations in lung cancer or p16 promoter methylation in 
esophageal cancer are not correlated with stage.31,32 Recently, 
circulating mutant DNA assessed after surgery and chemother-
apy in colorectal cancer using a bead emulsion amplification 
magnetics (BEAMing) assay combined with nested PCR and 
flowcytometric analysis revealed that quantities of circulating 
mutant DNA decline after surgery or chemotherapy with a half-
life of 114 minutes.33 That result suggests that the amount of 
circulating mutant DNA derived from cancer cells is correlated 
with total volume of tumor.
Because our systems for detecting EGFR mutations 
in plasma DNA are fully automated and noninvasive, they 
should be useful not only for detection before treatment with 
EGFR-TKI in advanced stage as an alternative method when 
peripheral blood is the only specimen available but also for 
monitoring during treatment with EGFR-TKI. Considering 
that the positive rate of EGFR mutation detection by our 
systems was not high using plasma DNA, cancer specimens 
should be the accepted standard for detection of mutations. 
However, we sometimes experience cases whose specimens 
are difficult to obtain, and most cases are at an advanced 
stage and inoperable. Our system could be useful as an alter-
native to the standard method in such situations.
Combining our novel EGFR activating/sensitive muta-
tion detection systems with the T790M detection system 
recently established in our laboratory, using plasma DNA, 
would be useful for deciding treatment, although monitoring 
of EGFR activating/sensitive mutations with T790M was per-
formed on only two cases. Using plasma DNA, detection of 
EGFR activating/sensitive mutations was correlated with the 
volume of cancer carrying those mutations, whereas T790M 
was observed in half of the patients who acquired resistance to 
EGFR-TKI. During or after treatment with EGFR-TKI, pres-
ence of EGFR activating/sensitive mutations and absence of 
T790M in plasma DNA is a promising predictive marker for 
retreatment with EGFR-TKI. Whether the combined detec-
tion systems have clinical relevance to deciding treatment is a 
remaining question requiring prospective study.
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